Women who are carriers of one of the BRCA1/2 cancer risk alleles are advised to have preventive surgery to stop ovarian cancer, but a new U.K. study reveals that extra surveillance can be effective in the short term for those who wish to delay surgery. The well-known BRCA1/2 gene variants…

A new variation of liquid biopsy technology claims to successfully boost ovarian cancer prediction in women with a cyst or other pelvic mass, according to a new study from the Wilmot Cancer Institute at the University of Rochester Medical Center published in Obstetrics & Gynecology “Green” journal. The approach improves the…

Scientists from the University of California (UC), San Diego, and their collaborators have demonstrated how key proteins act together to suppress antitumor activity in high-grade serous ovarian carcinoma (HGSOC) in a mouse model, revealing a new combinatorial strategy to treat this intractable malignancy. Hallmarks of a lethal form of ovarian…

Researchers at Helsinki University investigated how the genetic characteristics of ovarian cancer shape how tumor and immune cells communicate with each other and how BRCA1/2 mutations shape the cellular phenotypes and spatial interactions of the tumor microenvironment. “With the help of this revolutionary imaging technology and advanced data analysis, we…

Stem cell scientists have created fallopian tube-based organoids that may help predict which individuals with BRCA-1 mutations will develop ovarian cancer years or even decades in advance, and could be used to develop personalized therapies.   Their study was published this week in Cell Reports. Clive Svendsen, Ph.D., professor of…

UT Southwestern faculty say they have discovered what appears to be an Achilles’ heel in ovarian cancers, as well as new biomarkers that could point to which patients are the best candidates for possible new treatments. Their results suggest ribosome MARylation (the catalytic activity of mono-ADP-ribosyl-ates), promotes protein homeostasis in…

A new study in ovarian cancer found that using IgA-based antibodies produced by B cells may represent new immunotherapeutic agents for tumors resistant to conventional immune checkpoint blockade, which are currently focused on T cell-centric approaches. By design, immunotherapies are designed to boost the body’s T cells to recognize and…

Population-wide screening of younger women for hereditary breast and ovarian cancer (HBOC) may be more cost-effective than broadly testing older women, according to a new study in JAMA Network Open. Women between the ages of 20 and 35, the researchers found, have more time to take action to prevent these…

Screening for cancer, and catching it in the earliest possible stages, is a proven method of increasing survival odds for this deadly disease. However, most cancer screening tests are non-existent for patients lacking access to a clinic, even the increasingly reliable genetic screens that identify patients at greatest risk. Until…

Once ovarian cancer cells slough off from their site of origin, they tend to find a new home in tissues with high fat content. Now, researchers have shown that those ovarian cancer cells use fats as an energy source. At the heart of the transition to fatty acid metabolism is…

New advances in single cell RNA sequencing technology has brought researchers from the UK closer to discovering the cellular origin of a multitude of ovarian cancer subtypes, which they hope will eventually allow for the development a screening tool and better treatment options for this silent killer of women. Ovarian…

Myriad Genetics said today that its BRACAnalysis Diagnostic System has won a third regulatory approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) that will allow physicians to determine which women with breast cancer are at risk of having Hereditary Breast and Ovarian Cancer (HBOC) syndrome—and thus eligible for…

The FDA has approved Myriad Genetics’ myChoice CDx as a companion diagnostic for Zejula (niraparib) to identify women with advanced ovarian cancer in the late-line treatment setting—an indication added by the agency to its approved uses for the poly ADP-ribose polymerase (PARP) inhibitor marketed by GlaxoSmithKline (GSK). The FDA’s approval…

The FDA has approved an expanded indication for Foundation Medicine’s FoundationOne®CDx, authorizing the test as a companion diagnostic for the AstraZeneca/Merck & Co. co-developed Lynparza (olaparib) for first line maintenance therapy in BRCA-mutated advanced ovarian cancer. FoundationOne CDx is an FDA-approved comprehensive genomic profiling (CGP) test for all solid tumors…

Scientists at Uppsala University and the Sahlgrenska Academy, University of Gothenburg say they have developed a blood test that may provide a more precise diagnostic for suspected ovarian cancer that would eliminate the need for exploratory surgery. This could lead to a reduction in unnecessary surgery and to earlier detection…